| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff78110ee0cdcd8dcc5b611e508e557a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_990c39b81d69750b4444d89044f124b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a348fad857c56ab0540511261384af9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4821edf6953e49852d6802b0660b83c4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| filingDate |
1991-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cbdaaf520aad922d3e25afa5db44346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38802d132614691dcc140282945da903
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c650bad92e985bee99bf3154bfc79b50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25f16e0cd7ab58ef13841d1a3e9f4e20 |
| publicationDate |
1991-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2035155-A1 |
| titleOfInvention |
Pharmaceutical composition for the targeted controlled release of an active principle within the intestine, and particularly within the colon |
| abstract |
"PHARMACEUTICAL COMPOSITION FOR THE TARGETED CONTROLLED RELEASE OF AN ACTIVE PRINCIPLE WITHIN THE INTESTINE, AND PARTICULARLY WITHIN THE COLON." ABSTRACT The invention provides pharmaceutical compositions with the property of targeted controlled release of active principles which act pharmacologically within the intestine and in particular within the colon and the terminal portion of the ileum. To attain this object the active principle is prepared in multiparticle multidose form and is covered with at least two membranes, one of pH-dependent solubility and the other insoluble but permeable to the intestinal fluids. While the covered active principle remains in the stomach and in the initial intestinal portion, ie while the pH is less than 5.5, it is not released. Only when it reaches an environment of higher pH (small intestine or colon) does the pH-dependent membrane dissolve to commence release of the active principle. From this moment the second membrane, which is pH-independent but impermeable to the intestinal fluids, acts to slow down and control the dissolution of the medicament within the small intestine-colon tract. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8580302-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7763635-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8709476-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9089492-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7781448-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7781449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7759359-B2 |
| priorityDate |
1990-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |